Emerging therapies for ionizing radiation-associated skin field carcinogenesis

Pierard, Gérald; Piérard-Franchimont, C; Paquet, Philippe; Quatresooz, Pascale

doi:10.1517/14656560902754060

Cited by 8 publications

(1 citation statement)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pathogenic/etiological mechanisms are as yet unknown but involve the following mechanisms: (1) Ionizing radiation may result in mutations to mitochondrial and nuclear DNA, leading to chromosomal instability. Precursor and incipient neoplasms may later develop following these subclinical changes [ 29 ]. (2) Radiation may affect circulating lymphocytes and progenitor cells in the bone marrow [ 30 ].…”

Section: Discussionmentioning

confidence: 99%

Role of Radiation Therapy in Mortality among Adolescents and Young Adults with Lymphoma: Differences According to Cause of Death

Yin

You²,

Hu³

2022

Cancers

View full text Add to dashboard Cite

Background: Despite its efficacy, emerging concerns exist regarding radiation therapy (RT)-associated toxicity in adolescent and young adult (AYA) lymphoma patients. Few long-term follow-up studies have examined the association between RT and outcomes. Methods: Lymphoma patients aged 15–39 years were identified in the Surveillance, Epidemiology and End Results (SEER) database from 1992 to 2016. Mortality was assessed by comparing those with and without RT using the Fine–Gray competing risk model. Standardized mortality ratios (SMRs) were used to assess the relative risk of death compared with the general U.S. population. Results: In total, 29,686 patients were included; 10,708 (36.07%) received RT. Cause-specific mortality was compared between patients with and without RT while considering other competing events, including death due to index cancer, second malignant neoplasms (SMNs), and noncancer causes. Patients with RT had a lower probability of death and crude 5-year cumulative incidence of death. Moreover, there were significantly lower SMRs in patients with RT than in patients without RT. Differences between the two groups were greatest for mortality due to hematological malignancies and infections. Additionally, in the RT cohort, the SMR for index-cancer-related death was highest in the first year after diagnosis and gradually decreased. Hematological malignancies and infections were the most common specific SMN and noncancer causes of death, respectively. Conclusions: RT did not increase mortality from index cancer, SMNs, or noncancer causes in AYA patients with lymphoid malignancies. The current analysis may serve as a reference for healthcare providers monitoring RT application for AYA lymphoid malignancy survivors.

show abstract

Section: Discussionmentioning

confidence: 99%